September 7, 2021 -- NeuExcell Therapeutics and Spark Therapeutics are teaming up to develop a gene therapy for Huntington's disease.
Under the terms of the research collaboration agreement, Spark will gain access to NeuExcell's neuroregenerative gene therapy platform and will collaborate with NeuExcell's research team. In addition, NeuExcell is eligible to receive upfront, license fee, R&D, and sales milestone payments up to approximately $190 million plus product royalties. Spark has the option to license the exclusive worldwide rights to NeuExcell's Huntington's disease program.
NeuExcell is developing adeno-associated virus-based neuroregenerative gene therapy to regenerate functional new neurons at the site of the neurodegeneration, according to the companies.